Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Bonnefoi, A."'
Autor:
Michael S. Ewer, Richard D. Gelber, Masakazu Toi, Nicholas Wilcken, Marco Colleoni, Linda Reaby, Susan Dent, Guy Jerusalem, Sebastien Guillaume, Hans-Joachim Lueck, Investigators, Marion Procter, Eleonora Restuccia, Hervé Bonnefoi, Martine Piccart, Young-Hyuck Im, Michael Andersson, Estefania Monturus, Tsang Wu Liu, Evandro de Azambuja, Debora Fumagalli, José Bines, Ian E. Krop, Tadeusz Pienkowski, Emma Clark, Mihaela Sicoe, Christoph Thomssen, Ling Ming Tseng, Giuseppe Viale
Publikováno v:
Journal of Clinical Oncology. 39:1448-1457
PURPOSE APHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant trastuzumab and chemotherapy significantly improved invasive disease–free survival (IDFS) (hazard ratio 0.81 [95% CI, 0.66 to 1.00], P = .045) for patients wi
Publikováno v:
EMC - Neurologia. 21:1-16
Riassunto I movimenti anomali secondari rappresentano un vasto insieme semeiologico, che puo essere scomposto precisamente in sottogruppi, a seconda della tipologia del movimento anomalo (tic, distonia, corea/ballismo, miocloni, atetosi, ecc.), per o
Autor:
Charles E. Geyer, Andrés Redondo, Hervé Bonnefoi, Eleftherios P. Mamounas, Pierfranco Conte, Chiun-Sheng Huang, Gunter von Minckwitz, Thomas Boulet, Michael Untch, Priya Rastogi, Véronique D'Hondt, Tanya A. Wahl, Chunyan Song, Sibylle Loibl, Max S. Mano, Ljiljana Stamatovic, Peter Trask, Andreas Schneeweiss, Hans Holger Fischer, Norman Wolmark, Hugo Castro-Salguero
Publikováno v:
Cancer
Background The phase 3 KATHERINE trial demonstrated significantly improved invasive disease–free survival with adjuvant trastuzumab emtansine (T‐DM1) versus trastuzumab in patients with HER2‐positive early breast cancer and residual invasive di
Autor:
M. Campone, Bojana Stefanovska, Alexandra Jacquet, Fabrice Andre, M.P. Sablin, Hervé Bonnefoi, C. Le Tourneau, Isabelle Miran, Florence Dalenc, Cécile Jovelet, Thomas Bachelot, Amélie Lusque, F. Mosele, Nathalie Droin, A. Tran Dien, François Bertucci, Ivan Bièche, Diego Enrico, Ingrid Garberis, Jean-Charles Soria, M. Jimenez, Ludovic Lacroix
Publikováno v:
Annals of Oncology. 31:377-386
α-Selective phosphatidylinositol 3-kinase (PI3K) inhibitors improve outcome in patients with PIK3CA-mutated, hormone receptor-positive (HR+)/Her2- metastatic breast cancer (mBC). Nevertheless, it is still unclear how to integrate this new drug famil
Autor:
Tsang Wu Liu, Mihaela Sicoe, Giuseppe Viale, Hans-Joachim Lueck, Christoph Thomssen, Nicolas Wilcken, Michael S. Ewer, Evandro de Azambuja, Ian E. Krop, Estefania Monturus, Ling-Ming Tseng, Young-Hyuck Im, Debora Fumagalli, Marion Procter, Eleonora Restuccia, Hervé Bonnefoi, Tadeusz Pienkowski, Emma Clark, Marco Colleoni, Guy Jerusalem, Martine Piccart, Martin Andersson, Susan Dent, Linda Reaby, José Bines, Sébastien Guillaume, Richard D. Gelber, Masakazu Toi
Publikováno v:
Cancer Research. 80:GS1-04
Background: The APHINITY trial demonstrated that pertuzumab, when added to adjuvant trastuzumab and chemotherapy, modestly but statistically significantly improved invasive disease-free survival (IDFS) among patients with HER2-positive, operable brea
Autor:
Richard Iggo, Jean-Michel Picquenot, Denis Larsimont, Véronique Becette, Jonas Bergh, Gaëtan MacGrogan, Jeremy Thomas, Olivier Kerdraon, Leen Slaets, David Cameron, Fanny Pommeret, C. Poncet, Jean-Christophe Tille, Frédéric Bibeau, Hervé Bonnefoi, Alexandre Bodmer, Jean-Pierre Ghnassia, Thomas Grellety
Publikováno v:
British Journal of Cancer
British Journal of Cancer, Cancer Research UK, 2019, 120 (9), pp.913-921. ⟨10.1038/s41416-019-0420-y⟩
Bonnefoi, H, MacGrogan, G, Poncet, C, Iggo, R, Pommeret, F, Grellety, T, Larsimont, D, Becette, V, Kerdraon, O, Bibeau, F, Ghnassia, J-P, Picquenot, J-M, Thomas, J, Tille, J-C, Slaets, L, Bodmer, A, Bergh, J & Cameron, D 2019, ' Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes ', British Journal of Cancer . https://doi.org/10.1038/s41416-019-0420-y
British Journal of Cancer, 120 (9
British Journal of Cancer, Vol. 120, No 9 (2019) pp. 913-921
British Journal of Cancer, Cancer Research UK, 2019, 120 (9), pp.913-921. ⟨10.1038/s41416-019-0420-y⟩
Bonnefoi, H, MacGrogan, G, Poncet, C, Iggo, R, Pommeret, F, Grellety, T, Larsimont, D, Becette, V, Kerdraon, O, Bibeau, F, Ghnassia, J-P, Picquenot, J-M, Thomas, J, Tille, J-C, Slaets, L, Bodmer, A, Bergh, J & Cameron, D 2019, ' Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes ', British Journal of Cancer . https://doi.org/10.1038/s41416-019-0420-y
British Journal of Cancer, 120 (9
British Journal of Cancer, Vol. 120, No 9 (2019) pp. 913-921
Background: We explored, within the EORTC10994 study, the outcomes for patients with molecular apocrine (MA) breast cancer, and defined immunohistochemistry (IHC) as androgen-receptor (AR) positive, oestrogen (ER) and progesterone (PR) negative. We a
Autor:
Barbara Ruepp, Rupert Bartsch, Andrea Gombos, Frances M. Boyle, Giuseppe Viale, Anita Hiltbrunner, Thomas Bachelot, Martine Piccart-Gebhart, Caitlin Mahoney, Debora Fumagalli, Rina Hui, Theodora Goulioti, Fabrice Andre, Marco Colleoni, Carmen Comune, Magdelena Weber, Michelle Jenkins, Stefan Aebi, Stefania Andrighetto, Stamatina Fournarakou, Meredith M. Regan, Colleen King, Angelo Di Leo, Alan S. Coates, Rita Hui, Aron Goldhirsch, Mario Campone, Per Karlsson, Rolf A. Stahel, Vassiliki Karantza, Hui Huang, Laura Biganzoli, Hervé Bonnefoi, Sabrina Ribeli-Hofmann, Roswitha Kammler, Magdalena Sánchez-Hohl, Karolyn Scott, Patrick Schneier, Giuseppe Curigliano, Ingrid Kössler, Sherene Loi, Heather Findlay, Richard D. Gelber, Holly Shaw, Guy Jerusalem, Susan Fischer, Anita Giobbie-Hurder, Daniela Celotto, Manuela Rabaglio-Poretti, Rita Pfister, Michela Frapolli, Monica Greco, Adriana Gasca, Mark J. Smyth, Jaime A. Mejia, Karen N. Price, Heidi Roschitzki, Rudolf Maibach
Publikováno v:
The Lancet Oncology. 20:371-382
Summary Background HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be mediated by immune mechanisms. We assessed the safety and anti-tum
Autor:
Céline Charon-Barra, Corentin Richard, Laurent Arnould, Patrick Arveux, Hervé Bonnefoi, Françoise Beltjens, Catherine Loustalot, Emilie Degrolard-Courcet, Aurélie Bertaut, Anthony Bergeron, Gaëtan MacGrogan, Romain Boidot, Isabelle Desmoulins, Sophie Auriol, Sylvain Ladoire
Publikováno v:
Mod Pathol
Primary triple-negative invasive lobular breast carcinomas (TN-ILCs), which do not express hormone receptors and HER2 at diagnosis, are rare and poorly known. In this study, we analyzed the largest TN-ILC series ever reported in the literature, in co
Autor:
Bent Ejlertsen, Ines Vaz-Luis, Beat Thürlimann, Richard D. Gelber, Bernard F. Cole, Andrew M Wardley, Anita Giobbie-Hurder, Hervé Bonnefoi, Manuela Rabaglio, Marco Colleoni, Aron Goldhirsch, Vernon Harvey, Jose Pablo Leone, Meredith M. Regan, Patrick Neven, István Láng, Angelo Di Leo, Alan S. Coates, Nan Lin
Publikováno v:
CancerReferences. 127(5)
BACKGROUND Endocrine therapy resistance is a major cause of distant recurrence (DR) in hormone receptor-positive breast cancer. This study evaluated differences in survival after DR in patients treated with different adjuvant endocrine therapy regime
Autor:
Monica Castiglione, Vernon Harvey, Anita Giobbie-Hurder, Richard D. Gelber, István Láng, Andrew M Wardley, Barbara Ruepp, Alan S. Coates, Manuela Rabaglio, Marco Colleoni, Beat Thürlimann, Zhuoxin Sun, Hervé Bonnefoi, Patrick Neven, Meredith M. Regan, Bent Ejlertsen, Rudolf Maibach, Aron Goldhirsch
Publikováno v:
Rabaglio, M, Sun, Z, Maibach, R, Giobbie-Hurder, A, Ejlertsen, B, Harvey, V J, Neven, P, Láng, I, Bonnefoi, H, Wardley, A, Ruepp, B, Castiglione, M, Coates, A S, Gelber, R D, Goldhirsch, A, Colleoni, M, Thürlimann, B & Regan, M M 2021, ' Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence : a report from the BIG 1-98 trial ', Breast Cancer Research and Treatment, vol. 185, no. 3, pp. 697-707 . https://doi.org/10.1007/s10549-020-05981-z
BACKGROUND Compared to tamoxifen, adjuvant treatment with aromatase inhibitors improves disease outcomes of postmenopausal women with hormone receptor-positive early breast cancer. In the international, randomized, double-blind BIG 1-98 trial, 8010 w